Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study
Authors:
- Russell G. BuhrRBRussell G. Buhr
- Igor Z. BarjaktarevicIBIgor Z. Barjaktarevic
- Eugene R. BleeckerEBEugene R. Bleecker
- David J. CouperDCDavid J. Couper
- Jeffrey L. CurtisJCJeffrey L. Curtis
- Brett A. DolezalBDBrett A. Dolezal
- MeiLan K. HanMHMeiLan K. Han
- Nadia N. HanselNHNadia N. Hansel
- Jerry A. KrishnanJKJerry A. Krishnan
- Fernando J. MartinezFMFernando J. Martinez
- 1 September 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 206 (5) , 554-562
Abstract
Rationale: Chronic obstructive pulmonary disease (COPD) is defined by fixed spirometric ratio, FEV1/FVC < 0.70 after inhaled bronchodilators. However, the implications of variable obstruction (VO), in which the prebronchodilator FEV1/FVC ratio is less than 0.70 but increases to 0.70 or more after inhaled bronchodilators, have not been determined. Objectives: We explored differences in physiology, exacerbations, and health status in participants with VO compared with reference participants without obstruction. Methods: Data from the SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study) cohort were obtained. Participants with VO were compared with reference participants without obstruction. Measurements and Main Results: We assessed differences in baseline radiographic emphysema and small airway disease at study entry, baseline, and change in lung function by spirometry, functional capacity by 6-minute walk, health status using standard questionnaires, exacerbation rates, and progression to COPD between the two groups. All models were adjusted for participant characteristics, asthma history, and tobacco exposure. We assessed 175 participants with VO and 603 reference participants without obstruction. Participants with VO had 6.2 times the hazard of future development of COPD controlling for other factors (95% confidence interval, 4.6–8.3; P < 0.001). Compared with reference participants, the VO group had significantly lower baseline pre- and post-bronchodilator (BD) FEV1, and greater decline over time in post-BD FEV1, and pre- and post-BD FVC. There were no significant differences in exacerbations between groups. Conclusions: Significant risk for future COPD development exists for those with pre- but not post-BD airflow obstruction. These findings support consideration of expanding spirometric criteria defining COPD to include pre-BD obstruction. Clinical trial registered with www.clinicaltrials.gov (NCT 01969344).Keywords
Funding Information
- National Heart, Lung, and Blood Institute (HHSN268200900013C)
- National Heart, Lung, and Blood Institute (HHSN268200900014C)
- National Heart, Lung, and Blood Institute (HHSN268200900015C)
- National Heart, Lung, and Blood Institute (HHSN268200900016C)
- National Heart, Lung, and Blood Institute (HHSN268200900017C)
- National Heart, Lung, and Blood Institute (HHSN268200900018C)
- National Heart, Lung, and Blood Institute (HHSN268200900019C)
- National Heart, Lung, and Blood Institute (HHSN268200900020C)
- National Heart, Lung, and Blood Institute (U01HL137880)
- National Heart, Lung, and Blood Institute (U24HL141762)
- National Heart, Lung, and Blood Institute (L30HL134025)
- National Center for Advanced Translational Sciences (KL2TR001882)
- National Heart, Lung, and Blood Institute (HHSN268200900013C)
- National Heart, Lung, and Blood Institute (HHSN268200900014C)
- National Heart, Lung, and Blood Institute (HHSN268200900015C)
- National Heart, Lung, and Blood Institute (HHSN268200900016C)
- National Heart, Lung, and Blood Institute (HHSN268200900017C)
- National Heart, Lung, and Blood Institute (HHSN268200900018C)
- National Heart, Lung, and Blood Institute (HHSN268200900019C)
- National Heart, Lung, and Blood Institute (HHSN268200900020C)
- National Heart, Lung, and Blood Institute (U01HL137880)
- National Heart, Lung, and Blood Institute (U24HL141762)
- National Heart, Lung, and Blood Institute (L30HL134025)
- National Center for Advanced Translational Sciences (KL2TR001882)
This publication has 44 references indexed in Scilit:
- Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS): Table 1Thorax, 2013
- Computed tomography–based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progressionNature Medicine, 2012
- Barriers to adherence to COPD guidelines among primary care providersRespiratory Medicine, 2012
- Model selection and psychological theory: A discussion of the differences between the Akaike information criterion (AIC) and the Bayesian information criterion (BIC).Psychological Methods, 2012
- Development and first validation of the COPD Assessment TestEuropean Respiratory Journal, 2009
- Interval censoringStatistical Methods in Medical Research, 2009
- The MRC breathlessness scaleOccupational Medicine, 2008
- Bronchodilator responsiveness in patients with COPDEuropean Respiratory Journal, 2008
- Interpretative strategies for lung function testsEuropean Respiratory Journal, 2005
- Detection of asthma and chronic obstructive pulmonary disease in primary careEuropean Respiratory Journal, 2003